History and therapeutic rationale of long acting antipsychotics

Current Clinical Pharmacology

Volumn 9, Issue 1, 2014, Pages 39-52

  De Risio, Alessandro ^a   Lang, Antonella P ^a  

^a Department of Mental Health   (Italy)

Author keywords

Adherence; Atypical antipsychotics; History; Long acting injections; Pharmacology; Schizophrenia; Treatment; Typical antipsychotics

Indexed keywords

ARIPIPRAZOLE; BROMPERIDOL DECANOATE; CLOPENTHIXOL; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; FLUSPIRILENE; HALOPERIDOL DECANOATE; ILOPERIDONE; NEUROLEPTIC AGENT; OLANZAPINE; OXYPROTHEPINE DECANOATE; PALIPERIDONE; PENFLURIDOL; PERPHENAZINE ENANTHATE; PIPOTIAZINE PALMITATE; RISPERIDONE; ZUCLOPENTHIXOL ACETATE; ZUCLOPENTHIXOL DECANOATE;

DRUG ABSORPTION; DRUG EFFICACY; DRUG STRUCTURE; DRUG UTILIZATION; HISTORY OF MEDICINE; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL DEVELOPMENT; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; MEDICATION ADHERENCE; PSYCHOTIC DISORDERS; RECURRENCE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 84894031270     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748847113089990057     Document Type: Review

References (108)

1. Bazire S. Psychotropic drug directory, 2005. The professionals' pocket handbook & aide memoire. Salisbury, UK: Fivepin Limited 2005.
2. Adams CE, Fenton MKP, Quairashi S, David AS. Systematic metareview of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290-299.
3. Patel MX, David AS. Why aren't depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatr Treatment 2005; 11: 203-213.
4. Wheatley D. The history of psychotropic drugs in the United Kingdom. In: Ban TA, Healy D, Shorter E, Eds. The History of Psychopharmacology and the CINP as told in Autobiography, Vol. 4: Reflections on the Twentieth-Century Psycho-Pharmacology. CINP, East Kilbride, Scotland UK: 2004 p.83.
5. Sarwer-Foner GJ. Recognition and management of drug-induced extra-piramidal reactions and "paradoxical" behavioral reactions in psychiatry. Can Med Ass Journal 1960; 83, 312-318.
6. Hoffman L. One hundred years after Sigmund Freud's lectures in America: towards an integration of psychoanalytic theories and techniques within psychiatry. History Psychiatry 2010; 21: 455-470.
7. Warnes H. Reminiscences of the nineteen-sixties. In: Ban TA, Healy D, Shorter E, Eds. The History of Psychopharmacology and the CINP as told in Autobiography, Vol. 4: Reflections on the Twentieth-Century Psycho-Pharmacology. CINP, East Kilbride, Scotland UK 2004 pp.187-188.
8. Sarwer-Foner GJ. On the mechanisms of action of neuroleptic drugs: A theoretical psychodynamic explanation. In: Wortis J, Ed. Recent Advances in Biological Psychiatry (volume 6). Plenum Press, New York 1964 pp. 217-232.
9. Johnson DAW. Historical persepective on antipsychotic longacting injections. Br J Psychiatry 2009; 195: S7-S12.
10. Ong TC. Depot Neuroleptics. Sing Med J 1989; 30: 427-428.
11. Taylor D. Depot antipsychotic revisited. Psychiatr Bull 1999, 23: 551-553.
12. th World Congress of Psychiatry in Vienna. Lundbeck, Copenhagen 1984 pp. 9-14.
13. Brown WE, Wilder WM, Schwartz P. A study of oil used for intramuscular injections. J Lab Clin Med 1944; 29: 259-264.
14. Freni S. Aspetti psicodinamici del paziente in trattamento con neurolettici tipici e atipici: rilievi clinici e di ricerca. In: Freni S, Ed. Psicofarmacopsicoterapia. Prospettiva moderna per una prassi psichiatrica integrata. Edizioni La Vita Felice, Milano 1998 p. 184.
15. Dolnick E. Madness on the Couch. Blaming the Victim in Heyday of Psychoanalysis. Simon & Shuster, New York 1998.
16. Patel MX, Taylor M and David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry 2009; 195: S1-S4.
17. Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 2010; 11: 1-17.
18. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
19. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979; 36: 1283-1294.
20. Van Praag HM, Dols LCW. Fluphenazine enanthate and fluphenazine decanoate: a comparison of their duration of action and motor side effects. Am J Psychiatry 1973; 130: 801-804.
21. Denham J, Adamson L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatr Scand 1971; 47: 420-430.
22. Johnson DAW, Freeman HL. Long-acting tranquillisers. Practitioner 1972; 208: 395-400.
23. Pedersen V, Overø KF. The history of psychotropic drugs at Lundbeck. In: In: Ban TA, Healy D, Shorter E, Eds. The History of Psychopharmacology and the CINP as told in Autobiography, Vol. 4: Reflections on the Twentieth-Century Psycho-Pharmacology. CINP, East Kilbride, Scotland UK 2004, p. 53.
24. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry 2009; 195: s13-s19.
25. Gottfries GC, Green L. Fluphenthixol decanoate-in treatment of outpatients. Acta Psychiatr Scand Suppl 1974; 225: 15-24.
26. Awouters FHL, Lewi PJ. Forty Years of Antipsychotic Drug Research-from Haloperidol to Paliperidone-with Dr. Paul Janssen. Arzneimittel-Forschung (Drug Research) 2007; 57(10): 625-632.
27. Lòpez-Muñoz F, Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res Bull 2009; 79: 130-141.
28. Denber HC, Rajotte P, Kauffman D. Problems in evaluation of R 1625. Am J Psychiatry 1959; 116: 356-357.
29. Granger B, Albu S. The haloperidol story. Ann Clin Psychiatry 2005; 17: 137-140.
30. Leong OK, Wong KE, Tay WK, Gill RC. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Sing Med J 1989; 30: 436-440.
31. Ayd F. Long-acting injectable neuroleptics. Psychopharmacol Rev 1972; 1-2: 1-6.
32. Simpson GM. A brief history of depot neuroleptics. J Clin Psychiatry 1984; 45(5 Pt 2): 3-4.
33. Janssen PAJ. Function and dysfunction of the basal ganglia. In: Ban TA, Healy D, Shorter E. (Eds.). The Rise of Psychopharmacology and the Story of CINP. Volume 1 of the Series: The History of Psychopharmacology As Told in Autobiography. CINP, East Kilbride, Scotland UK 1998, p. 67.
34. Lapierre YD. a controlled study of penfluridol in the treatment of schizophrenia. Am J Psychiatry 1978; 135: 956-959.
35. Lapierre YD, Joned BD. Pharmacological treatment of the negative symptoms of schizophrenia. In: Shriqui CL, Nasrallah HA (eds.) Contemporary Issues in the Treatment of Schizophrenia. The American Psychiatric Press, Washington, DC 1996.
36. Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ, doi: 10.1136/bmj.38881. 382755.2F (published 6 July 2006).
37. Vinar O. My memories of early psychiatric drug development. In: Ban TA, Healy D, Shorter E. (Eds.). The Rise of Psychopharmacology and the Story of CINP. Volume 1 of the Series: The History of Psychopharmacology As Told in Autobiography. CINP, East Kilbride, Scotland UK 1998 p. 229.
38. Benešová O. Psychopharmacology was my destiny. In: Ban TA, Healy D, Shorter E. (Eds.). The Rise of Psychopharmacology and the Story of CINP. Volume 1 of the Series: The History of Psychopharmacology As Told in Autobiography. CINP, East Kilbride, Scotland UK 1998 p. 227.
39. Protiva M. Origin and development of the Czech psychotropic agents in the 1960s. In: Ban TA, Healy D, Shorter E. (Eds.). The Rise of Psychopharmacology and the Story of CINP. Volume 1 of the Series: The History of Psychopharmacology As Told in Autobiography. CINP, East Kilbride, Scotland UK 1998 p. 226.
40. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009; 119: 4-14.
41. Olivares JM, Pinal B, Cinos C. Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia. Neuropsychiatry 2011; 1(3): 275-289
42. Glazer WM. Who Receives Long-Acting Antipsychotic Medications? Psychiatr Serv 2007; 58: 437.
43. Davis JM. The use of depot medications in the treatment of schizophrenia. Am J Psychiatry 2010; 167; 2: 126.
44. Janssen PAJ. The chemical anatomy of neuroleptic drugs. Särtryck Farmaceutisk Revy 1966; 65: 1-23.
45. Janssen PAJ. The butyrophenone story. In: Ayd FJ, Blackwell B. (Eds.). Discoveries in Biological Psychiatry. Ayd Medical Communications, Baltimore, MD 1984 pp. 165-179.
46. Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry 2009; 195: S29-S36.
47. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007; 115: 260-7.
48. Gilday E, Nasrallah HA. Clinical Pharmacology of Paliperidone Palmitate A Parenteral Long-Acting Formulation for the Treatment of Schizophrenia. Reviews on Recent Clin Trials 2012; 7: 2-9.
49. Alphs L, Bossie CA, Sliwa JK, Ma Y-W, Turner N. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry 2011; 10: 12.
50. Ortho-McNeil-Janssen Pharmaceuticals. Invega Sustenna (paliperidone palmitate) extended release injectable suspension: prescribing information. Available from URL: http://www. invegasustenna.com/invegasustenna/shared/pi/invegasustenna.pdf
51. Cocoman A, Murray J. Intramuscular injections: a review of best practice for mental health nurses. J Psychiatr Men Health Nurs 2008; 15: 424-434.
52. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010; 167: 181-189.
53. Naber D. Olanzapine pamoate for the treatment of schizophrenia. Expert Opin Pharmacother 2011; 12(4): 627-633.
54. Food and Drug Administration. Psychopharmacologic Drugs Advisory Committee Meeting. FDA, 2008. Available at: www.fda. gov/ohrms/dockets/ac/08/briefing/2008-4338b1-01-fda.pdf).
55. Kane JM, Garcia-Ribera C. Clinical guidelines recommendations for antipsychotic long-acting injections. Br J Psychiatry 2009; 195: S63-S67.
56. Granger B, Albu S, Benyaya J. Antipsicóticos (III). La consolidación de la terapéutica neuroléptica: la introducción clínica del haloperidol y el desarrollo de las butirofenonas y tioxantenos. In: López-Muñoz F., Alamo C. (Eds.) Historia de la Psicofarmacología. Editorial Médica Panamericana, Madrid, Spain 2007; pp.651-668.
57. Nahata T, Saini TR. Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design. PDA J Pharm Sci Technol 2009; 63(2): 113-122.
58. Kane J. Efficacy of aripiprazole-intramuscular-depot for the longterm maintenance treatment of schizophrenia. APA 2012; Abstract NR6-41.
59. Fleischhacker W. Long-term safety and tolerability of one-monthly aripiprazole-intramuscular-depot for the long-term maintenance treatment of schizophrenia. APA 2012; Abstract NR4-47.
60. th July, 2012, from URL: http://www.zysis.com/wpcontent/ uploads/2011/09/ZY102-Non-Confidential-Partnering-Slide-Review-2011.pdf
61. Gründer G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 2008; 165: 988-995.
62. th July, 2012, from URL: http://www.zysis.com/wp-content/uploads/2011/09/ZY102-Executive-Summary.pdf
63. st July, 2012, from URL: http://clinicaltrials.gov/ct2/show/ NCT01416441.
64. Bishop JR, Bishop DL. Iloperidone for the treatment of schizophrenia. Drugs Today (Barc) 2010; 46(8): 567-579.
65. Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther 2010; 4: 33-48.
66. Weiden PJ. Iloperidone for the Treatment of Schizophrenia: An Updated Clinical Review. Clin Schizophr Rel Psychoses 2012; 34-44.
67. th July, 2012, from URL: http://regulatoryaffairs.pharmaceutical-business-review.com/news/
68. st Annual Meeting of American Psychiatric Association; May 3-8, 2008; Washington, DC.
69. Walburn J, Gray R, Gournay K, Quairashi S, David AS. Systematic review of patient and nurses attitudes to depot antipsychotic medication. Br J Psychiatry 2001; 179; 300-307.
70. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotics for schizophrenia-A critical systematic review and meta-analysis of randomized long-term trials. Schizophr Res 2010; 127; 83-92.
71. Lambert TJ, Singh BS, Patel MX. Community treatment orders and antipsychotic long-acting injections. Bri J Psychiatry 2009; 195: S57-S62.
72. Rabboni M, Petrera C. Fra buone pratiche e linee di qualità per un modello di riabilitazione. II-Comparazione tra modelli nazionali, europei e del nuovo mondo. Errepiesse 2009; 3: 5-16.
73. Jaeger M, Rossler W. Attitude towards long-acting depot antipsychotics: a survey of patiens, relatives and psychiatrists. Psychiatr Res 2010; 175: 58-62.
74. Dalmotto M, Pirfo E. Haloperidol decanoate and long-acting injectable risperidone: subjective experience of outpatients with schizophrenia. Giorn Ital Psicopat 2010; 16: 299-304.
75. Patel MX, Nikolau V, David AS. Psychiatrists' attitudes to maintence medication for patients with schizophrenia. Psychol Med 2003; 33: 83-9.
76. Burns T. Knowledge about antipsychotic long-acting injections: bridging the gap. Br J Psychiatry 2009; 195: S5-S6.
77. Manchanda N, Herman C. Decision Resources. Cognos Study#5. A Pharmacor Service. Schizophrenia, November 2006. Decision Resources, Inc., Waltham, Massachussets 2006, pp.86-88.
78. Nuvoli G., Lombardi D. Il trattamento depot in ambito territoriale: caratteristiche cliniche, socio-demografiche e di genere. Giorn Ital Psicopat 2011; 17(S1): 163.
79. AIFA-Ministero della salute. Farmacovigilanza dei farmaci antipsicotici con la partecipazione dei familiari. Bif 2006; 3: 99-105.
80. De Martis D, Ambrosi P, Vender S. Fattori relazionali e culturali dell'uso dei neurolettici long-acting nella terapia dei pazienti psicotici cronici. In: Rovera GG, Fassino S (Eds.), Atti del Congresso a partecipazione Internazionale: Psicopatologia e farmaci. interazioni somatiche, psicologiche e sociali. Centro Scientifico Editore, Torino 1988 pp. 142-147.
81. Simões do Cuto F, Queiroz C, Barbosa T, et al. Clinical and therapeutic characterization of a portuguese sample of patients with schizophrenia. Actas Esp Psiquiatr 2011; 39: 147-154.
82. Niaz OS, Haddad PM. Injectable long-acting antipsychotics (LAI). In: Mortimer AM, McKenna PJ (Eds.). The Year in Schizophrenia, 2010. Atlas Medical Publishing, Ltd., Oxford, UK 2010.
83. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv 2007; 58: 1187-1192.
84. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992; 53: 426-433.
85. Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists' use, knowledge and attitudes to first and second generations antipsychotic long-acting injections: comparison over five years. J Psychopharmacol 2010; 24: 1473-1482.
86. Lasser RA, Schooler NR, Kujawa M, Jarboe K, Docherty J, Weiden P. A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy. Psychiatry (Edgemont) 2009; 6(4): 22-27.
87. Amador X. I Am Not Sick, I Don't Need Help! How to Help Someone with Mental IllnessAccept Treatment, Second Edition. Vida Press, Peconic (New York) 2006.
88. Paillot C, Goetz R, Amador, X. Double-blind, randomized, controlled study of a psychotherapy designed to improve motivation for change, insight into schizophrenia and adherence to medication. Schizophr Bull 2009; 35(1): 343.
89. Thyssen A, Rusch S, Herben V, Quiroz J, Mannaert E. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J Clin Pharmacol 2010; 50: 1011-1021.
90. Peng X, Ascher-Svanum A, Faries D, Conley RR, Schuh KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clin Econ Outcomes Res 2011; 3: 9-14.
91. Ravasio R, Sanfilippo L, De Paoli G, Cerra C, Fratino P, Della Giovanna M. Analisi di costo-efficacia dello switch da un antipsicotico orale a risperidone a rilascio prolungato nel trattamento dei pazienti affetti da schizofrenia. Giorn Ital Health Technol Ass 2009; 2(1): 1-8.
92. Reichhart T, Kissling W. Societal Costs of Non-Adherence in Schizophrenia: Homicide/Suicide. M&B 2010; 1: 19-22.
93. Muldoon C. Preventing local complications of depot neuroleptics. BMJ 1995; 311: 1368.
94. David A, Quraishi S, Rathbone J. Enantato y decanoato de perfenazina de depósito para la esquizofrenia (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.updatesoftware. com. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.). Retrieved, July 31th, 2012, from: http://www.update-software.com/BCP/BCPGet Document.asp?DocumentID=CD001717 [Span.].
95. Taylor D, Paton C, Kerwin R. The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust. Prescribing Guidelines, 10th Edition. Informa Healthcare, London, United Kingdom 2009.
96. Bártová D, Buresová A, Hajnová R, Svestka J, Tichý P. The effect of oxyprothepine decanoate, lithium and cyproterone acetate on deviant sexual behavior. Cesk Psychiatr 1986; 82(6): 355-60.
97. European Medicines Agency. Assessment Report for Zypadhera. Retrieved, 23 July 2012, from URL: http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR_-_Public_assessment_report/ human/000890/WC500054428.pdf
98. Kostansky JW, Matsuda T, Nerukar M, Naringrekar VH. Controlled release sterile injectable aripiprazole formulation and method. United States Patent Application Publication, Pub. No. 2012/0100190 A1, Apr. 26, 2012.
99. Turner EH, Knoepflmacher D, Shapley L. Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database. PLoS Med 2012; 9(3): e1001189. doi: 10.1371/journal. pmed.1001189.
100. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2009; 63: 1237-48.
101. Meise U, Kurz M, Fleischhacker WW. Antipsychotic Maintenance Treatment of Schizophrenia Patients: Is There a Consensus?. Schizophr Bull 1994; 20(1): 215-225.
102. Brunot A, Lachaux B, Sontag H, et al. Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia. Encephale 2002; 28(2): 129-138.
103. Llorca PM, Miadi-Fargier H, Lançon C, et al. Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation. Encephale 2005; 31(2): 235-246.
104. Bret P, Heil M, Queuille E, Bret MC. Réseau Pic. Collaborators (10). Evaluation of prescription practices of long acting injectable risperidone in French hospitals. Encephale 201; 37(Suppl 1): S58-65.
105. Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Clinical and Social Determinants of Use of Depot Antipsychotics for Patients with Schizophrenia in Hong Kong. Hong Kong J Psychiatry 2006; 16: 71-75.
106. Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China. Int J Clin Pharmacol Ther 2008; 46(5): 245-251.
107. Virit O, Altindag A, Bulbul F, Savas HA, Dalkilic A. Long-Acting Typical and Atypical Antipsychotics in Treatment of Schizophrenia: A Retrospective Comparison. Bull Clin Psychopharmacol 2009; 19: 119-127.
108. Bartzokis G, Lu PH, Amar P et al. Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res 2011; 132: 35-41.